GNRH1 and prostate cancer: The observational research design has limitations as does the inability to examine the usage of oral anti-androgens [22]. According to Efstathiou et al., a longer duration of adjuvant GnRH agonist medication does not improve cardiovascular mortality in males with locally advanced prostate cancer, whereas traditional cardiac risk factors, such as DM, prevalent CVD, and age, were significantly associated with higher cardiovascular mortality [20].